Boston Scientific Corp. Announces Executive and Director Changes

Ticker: BSX · Form: 8-K · Filed: 2025-10-23T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, executive-changes, director-election

Related Tickers: BSX

TL;DR

BSX leadership shakeup: new directors elected, exec comp adjusted.

AI Summary

Boston Scientific Corporation (BSX) announced on October 22, 2025, changes in its executive and director roles. The filing details the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for key executives. Specific names and financial details related to these changes are not provided in this excerpt.

Why It Matters

Changes in leadership and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — The filing reports routine corporate governance changes, such as director elections and executive appointments, which typically carry low risk.

Key Players & Entities

FAQ

What specific roles have been affected by the departure of officers or directors?

The filing indicates departures of certain officers and directors, but does not specify the exact roles in this excerpt.

Who are the newly elected directors?

The filing states that directors have been elected, but their names are not provided in this excerpt.

Are there any changes to executive compensation arrangements?

Yes, the filing mentions compensatory arrangements of certain officers have been adjusted.

What is the date of the earliest event reported in this 8-K?

The date of the earliest event reported is October 22, 2025.

What is the company's IRS Employer Identification Number?

The IRS Employer Identification Number for Boston Scientific Corporation is 04-2695240.

From the Filing

0000885725-25-000048.txt : 20251023 0000885725-25-000048.hdr.sgml : 20251023 20251023162146 ACCESSION NUMBER: 0000885725-25-000048 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20251022 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20251023 DATE AS OF CHANGE: 20251023 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 251413355 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 8-K 1 bsx-20251022.htm 8-K bsx-20251022 0000885725 false 0000885725 2025-10-22 2025-10-22 0000885725 us-gaap:CommonStockMember 2025-10-22 2025-10-22 0000885725 bsx:SeniorNotedue2027Member 2025-10-22 2025-10-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 _____________________________________________________________________ Date of Report (Date of earliest event reported): October 22, 2025 BOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter) Delaware 1-11083 04-2695240 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)      300 Boston Scientific Way , Marlborough , Massachusetts                  01752-1234     (Address of principal executive offices)                           (Zip Code) ( 508 ) 683-4000 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.01 par value per share BSX New York Stock Exchange 0.625% Senior Notes due 2027 BSX27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company    ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 22, 2025, John E. Sununu informed Boston Scientific Corp

View on Read The Filing